Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06402708 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)

StatusRecruiting
PhasePhase 3
Started2024-04-09
View on ClinicalTrials.gov ↗

Amendment history

2026-04-22
Study Status v2
Re-verified, no change to tracked fields
2024-05-08
Study Status, Study Description v1
Study description-7 characters
[...] TPF with 2/3 of standard dose was well tolerance. Therefore, we decided to take medium dose of TPF three drugs chemotherapy were chosed to balance efficacy and toxicity.
2024-05-03
Original filing
Fudan University
624 trials monitored
See 9 trials at risk
The goal of this clinical trial is to learn the role of adjuvant chemotherapy for patients with thymic carcinoma and completed resection. The main questions it aims to answer are: 1. Does adjuvant chemotherapy decrease disease progression? 2. Does medium dose of three drugs (paclitaxel, cisplatin, 5-FU) well tolerance? Researchers will compare chemoradiotherapy to radiotherapy to see whether chemoradiotherapy could decrease disease progression or not. Participants will: 1. Take radiotherapy (50Gy/25f) with or without 4 cycles of chemotherapy (TPF). 2. Follow up every 3 months in the first two year, and then every 6 months.
Trial Details
NCT Number NCT06402708
Lead Sponsor Fudan University
Conditions Thymic Carcinoma
Enrollment 172 participants
Start Date 2024-04-09
Primary Completion 2027-05-01 (estimated)
Study Completion 2030-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-27